{"disease":{"id":"perioperative-mydriasis","name":"Perioperative Mydriasis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":6,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"atropin","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enlon-Plus","generic_name":"Atropin","company_name":"Alcon Labs Inc","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Non-Standardized Insect Allergenic Extract [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"cyclopentolate","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cyclogyl","generic_name":"CYCLOPENTOLATE","company_name":"Alcon Labs Inc","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"cyclopentolate","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"lomotil","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enlon-Plus","generic_name":"Atropine Sulfate","company_name":"Alcon Labs Inc","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptors","drug_class":"Antimuscarinic agent","quality_score":62,"revenue":null,"mechanism":"Atropine antagonizes muscarine-like actions of acetylcholine through competitive antagonism at peripheral muscarinic receptors."},{"drug_id":"atropine","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Enlon-Plus","generic_name":"ATROPINE","company_name":"Mmt","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M3","drug_class":"Anticholinergic","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"homatropine","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Homatropin","generic_name":"homatropine","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Muscarinic Antagonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"scopolamin","indication_name":"Perioperative Mydriasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"scopolamin","company_name":"University Hospital, Angers","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"lomotil","guideline_body":"FDA label","recommendation":"Atropine Sulfate Injection, USP, is indicated for perioperative mydriasis.","line_of_therapy":"any","evidence_grade":"C","guideline_year":null},{"drug_id":"lomotil","guideline_body":"FDA label","recommendation":"Atropine Sulfate Injection, USP, is indicated for temporary blockade of severe or life threatening muscarinic effects, such as in cases of organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest.","line_of_therapy":"1L","evidence_grade":"C","guideline_year":null}],"source":"Drug Landscape verified database"}